skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon
3,000
お客様の企業数
300
専属アナリスト数
175
データベースがカバーしている国数
248,000
データベースが収録する臨床試験数

インフォーマ・ファーマインテリジェンス

ファーマインテリジェンスは、インフォーマ(Informa PLC)のインフォーマインテリジェンス部門の中で製薬産業に関する情報を扱っている部門です。米国、欧州5か国(イギリス、フランス、ドイツ、イタリア、スペイン)、日本の計7つの市場を中心に医療用医薬品や医療機器の市場予測、世界中の開発パイプラインや臨床試験情報などのデータベース、世界の製薬産業や薬事規制、承認審査に関するニュース配信サービスなどを提供しています。

インフォーマインテリジェンス部門では、医薬品産業の他に金融、情報通信、海事、農業分野における市場調査および情報データベースの提供を行っています。

インフォーマ・ファーマインテリジェンスの強み

アナリスト&ジャーナリスト

お客様の声・ケーススタディ

"RxScorecard™ lets a biopharma company anticipate the most important factors impacting the clinical & economic value of pipeline and marketed drugs -- and then helps identify the necessary changes to the clinical development and commercial program to maximize that value for all stakeholders, especially including payers. It's a required, straightforward, objective strategic tool that allows us to quickly and effectively adapt to a rapidly changing and much more challenging market access environment."

​Ammar Qadan ​Global Value/Market Access Lead Oncology Portfolio & Global Commercial Lead Oncology Biomarkers Halozyme Therapeutics, Inc.

"RxScorecard™ provides a comprehensive, multi-pronged rubric assisting us in decision-making as we begin to move from a volume to value drug evaluation methodology."

​Chronis H. Manolis, RPh ​Vice President, Pharmacy UPMC Health Plan

“With pharmacy costs increasing so quickly, there is increasing pressure for P&T and Technology Assessment Committees to consider the value as well as the clinical efficacy of the drugs under evaluation. By providing an objective framework for assessing value, RxScorecard™ fills a gap in the existing toolkit available to health plans. And with greater discussion around narrower formularies, RxScorecard™ becomes even more important.”

​Michael S. Sherman, MD, MBA ​Senior Vice President and Chief Medical Officer Harvard Pilgrim Health Care

"We at GSK believe that it’s critical for the pharmaceutical industry to produce drugs that deliver value for patients, providers and payers. We have found RxScorecard™ to be an insightful framework for assessing and comparing the value of drugs, both marketed and developmental assets. The perspective it provides supports improved customer-focused development and commercialization, and we and our customers can benefit from its use.”

​Jack Bailey ​President GlaxoSmithKline U.S.